Skip to main content

Tarsus Pharmaceuticals, Inc.

TARS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001819790

In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tarsus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
4 insiders, $5.19M in total
Insiders trading
4
Net value
−$5.19M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tarsus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tarsus Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Pyott David E IDirector9,575IndirectSep 17, 20264
Yarno Wendy LDirector16,956Sep 17, 20263
Link William J PhDDirector94,487Sep 17, 20266
Azamian Bobak R.President/CEO and Board Chair827,991IndirectSep 9, 20268
Lin Elizabeth YeuChief Medical Officer1,590IndirectSep 9, 20266
Neervannan SeshadriChief Operating Officer78,532Sep 9, 20267
Chaudhuri BhaskarDirector11,654Jun 29, 20262
Morrison Scott WDirector7,638Jun 29, 20262
Goldberg Andrew D.Director19,654Jun 29, 20262
Goodrich KatherineDirector2,233Jun 29, 20264
Farrow Jeffrey SSee Remarks56,801Jun 17, 20264
Mottiwala AzizChief Commercial Officer61,480Mar 19, 20263
Whitfield Dianne C.Chief Human Resources Officer35,028Mar 19, 20265
Wahl BryanGeneral Counsel63,959Mar 19, 20263
Crane Rosemary ADirector5,350Jun 25, 20240
Trevejo Jose M.CHIEF MEDICAL OFFICER2,251Dec 22, 20230
Greenstein Leonard M.Chief Financial Officer26,785Apr 21, 20230
Holdbrook Mark J.V.P., Clinical Affairs3,191Mar 21, 20230
Ackermann MichaelDirector1,208,273Jul 1, 20220
Vivo Capital Fund IX, L.P.10% Owner2,469,001IndirectMay 5, 20220
Vivo Capital IX, LLC10% Owner2,469,001IndirectMay 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 6, 2021 (view filing)Aug 51 dayAzamian Bobak R.President and CEOSSale−1.37K$25.00−$34.3K−0.1%1.23M after
Aug 6, 2021 (view filing)Aug 51 dayAckermann MichaelDirectorSSale−1.38K$25.00−$34.6K−0.1%1.23M after3 lots
Aug 10, 2021 (view filing)Aug 6-94 daysAzamian Bobak R.President and CEOSSale−2.44K$25.01−$61.1K−0.2%1.23M after3 lots
Aug 10, 2021 (view filing)Aug 6-94 daysAckermann MichaelDirectorSSale−3.83K$25.00−$95.7K−0.3%1.23M after2 lots
Aug 12, 2021 (view filing)Aug 10-112 daysAzamian Bobak R.President and CEOSSale−2.02K$25.07−$50.6K−0.2%1.23M after2 lots
Aug 12, 2021 (view filing)Aug 111 dayAckermann MichaelDirectorSSale−621$25.15−$15.6K−0.1%1.23M after
Sep 3, 2021 (view filing)Sep 12 daysAckermann MichaelDirectorSSale−5.83K$25.24−$147.2K−0.5%1.22M after
Sep 3, 2021 (view filing)Sep 12 daysAzamian Bobak R.President and CEOSSale−5.83K$25.25−$147.3K−0.5%1.22M after2 lots
Sep 14, 2021 (view filing)4:51 PM ETSep 104 daysMottiwala AzizChief Commercial OfficerSSale−2.59K$22.15−$57.4K−4.3%58.2K after
Oct 12, 2021 (view filing)Oct 84 daysAzamian Bobak R.President and CEOSSale−302$25.02−$7.56K0.0%1.22M after
Oct 12, 2021 (view filing)Oct 84 daysAckermann MichaelDirectorSSale−200$25.03−$5.01K0.0%1.22M after
Oct 14, 2021 (view filing)Oct 122 daysAzamian Bobak R.President and CEOSSale−5.53K$26.30−$145.4K−0.5%1.22M after2 lots
Oct 14, 2021 (view filing)Oct 122 daysAckermann MichaelDirectorSSale−5.63K$26.27−$148.0K−0.5%1.22M after2 lots
Nov 3, 2021 (view filing)Nov 12 daysAzamian Bobak R.President and CEOSSale−5.83K$27.82−$162.3K−0.5%1.21M after2 lots
Nov 3, 2021 (view filing)Nov 12 daysAckermann MichaelDirectorSSale−5.83K$27.82−$162.3K−0.5%1.21M after2 lots
Nov 4, 2021 (view filing)Nov 22 daysMottiwala AzizChief Commercial OfficerSSale−6.00K$26.78−$160.7K−10.3%52.2K after2 lots
Nov 8, 2021 (view filing)Nov 4-54 daysMottiwala AzizChief Commercial OfficerSSale−111$28.04−$3.11K−0.2%52.1K after2 lots
Nov 10, 2021 (view filing)Nov 82 daysMottiwala AzizChief Commercial OfficerSSale−1.89K$28.11−$53.1K−3.6%50.2K after
Dec 3, 2021 (view filing)Dec 12 daysAzamian Bobak R.President and CEOSSale−5.83K$24.72−$144.2K−0.5%1.20M after4 lots
Dec 3, 2021 (view filing)Dec 12 daysAckermann MichaelDirectorSSale−5.83K$24.68−$143.9K−0.5%1.20M after4 lots
May 4, 2022 (view filing)8:01 PM ETMay 2-42 daysVivo Capital Fund IX, L.P. and 1 other10% OwnerSSale−513.0K$13.39−$6.87M−17.2%2.47M after3 lots
May 5, 2022 (view filing)6:55 PM ETMay 5Same dayVivo Capital Fund IX, L.P. and 1 other10% OwnerSSale−5.37K$12.25−$65.8K−0.2%2.47M after
May 9, 2022 (view filing)May 54 daysAckermann MichaelDirectorPPurchase+100.0K$13.50+$1.35MNew position100.0K after
Aug 19, 2022 (view filing)Aug 181 dayGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$16.30−$81.5K−7.2%64.3K after
Aug 19, 2022 (view filing)Aug 172 daysAzamian Bobak R.President and CEOSSale−8.00K$16.59−$132.7K−0.7%1.20M after2 lots
Sep 16, 2022 (view filing)Sep 151 dayGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$16.03−$80.2K−7.8%59.3K after
Sep 16, 2022 (view filing)Sep 142 daysLin Elizabeth YeuDirectorPPurchase+18.4K$16.12+$296.6KNew position6.36K after2 lots
Sep 16, 2022 (view filing)Sep 142 daysAzamian Bobak R.President and CEOSSale−9.00K$16.01−$144.1K−0.8%1.19M after
Sep 23, 2022 (view filing)Sep 212 daysAzamian Bobak R.President and CEOSSale−8.00K$16.31−$130.5K−0.7%1.18M after2 lots
Oct 14, 2022 (view filing)Oct 122 daysAzamian Bobak R.President and CEOSSale−9.00K$15.91−$143.2K−0.8%1.17M after2 lots
Oct 21, 2022 (view filing)Oct 192 daysAzamian Bobak R.President and CEOSSale−8.00K$16.92−$135.3K−0.7%1.16M after2 lots
Oct 28, 2022 (view filing)Oct 208 daysLateGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$15.92−$79.6K−8.4%54.3K after2 lots
Nov 14, 2022 (view filing)Nov 95 daysAzamian Bobak R.President and CEOSSale−9.00K$17.87−$160.8K−0.8%1.15M after
Nov 17, 2022 (view filing)Nov 152 daysMottiwala AzizChief Commercial OfficerSSale−6.86K$17.72−$121.5K−12.1%49.7K after
Nov 18, 2022 (view filing)Nov 171 dayGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$16.54−$82.7K−9.2%49.3K after
Nov 18, 2022 (view filing)Nov 162 daysAzamian Bobak R.President and CEOSSale−8.00K$16.86−$134.9K−0.7%1.15M after2 lots
Dec 1, 2022 (view filing)Nov 30-Dec 11 dayWhitfield Dianne C.Chief Human Resources OfficerSSale−2.35K$16.62−$39.0K−19.2%9.88K after2 lots
Dec 1, 2022 (view filing)Nov 30-Dec 11 dayWahl BryanGeneral CounselSSale−2.35K$16.62−$39.0K−13.6%14.9K after2 lots
Dec 6, 2022 (view filing)Dec 24 daysWhitfield Dianne C.Chief Human Resources OfficerSSale−1.15K$16.90−$19.5K−11.7%8.72K after
Dec 6, 2022 (view filing)Dec 24 daysWahl BryanGeneral CounselSSale−1.15K$16.90−$19.5K−7.8%13.7K after
Dec 16, 2022 (view filing)Dec 151 dayGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$14.64−$73.2K−10.1%44.3K after
Dec 16, 2022 (view filing)Dec 142 daysAzamian Bobak R.President/CEO and Board ChairSSale−6.42K$15.08−$96.8K−0.6%1.14M after
Dec 20, 2022 (view filing)Dec 164 daysAzamian Bobak R.President/CEO and Board ChairSSale−535$15.01−$8.03K0.0%1.14M after
Dec 22, 2022 (view filing)Dec 211 dayAzamian Bobak R.President/CEO and Board ChairSSale−8.00K$14.57−$116.6K−0.7%1.13M after
Jan 11, 2023 (view filing)Jan 9-102 daysAzamian Bobak R.President/CEO and Board ChairSSale−1.63K$15.16−$24.8K−0.1%1.13M after2 lots
Jan 13, 2023 (view filing)Jan 112 daysAzamian Bobak R.President/CEO and Board ChairSSale−3.90K$15.11−$59.0K−0.3%1.12M after
Jan 20, 2023 (view filing)Jan 191 dayGreenstein Leonard M.Chief Financial OfficerSSale−5.00K$14.56−$72.8K−11.3%39.3K after
Jan 20, 2023 (view filing)Jan 18-202 daysAzamian Bobak R.President/CEO and Board ChairSSale−8.24K$14.57−$120.1K−0.7%1.12M after2 lots
Jan 24, 2023 (view filing)Jan 618 daysLateAzamian Bobak R.President/CEO and Board ChairSSale−411$15.00−$6.17K0.0%1.13M after
Jan 25, 2023 (view filing)Jan 232 daysAzamian Bobak R.President/CEO and Board ChairSSale−4.86K$15.45−$75.0K−0.4%1.11M after